Bibliometric Evaluation Based On Scopus Database: A Global Analysis of Publications on Myelodysplastic Syndrome and Evaluation of Publications From Turkey

Öz

Aim: Myelodysplastic syndromes (MDS) include a group of hematological malignancies characterized by clonal hematopoiesis, one or more cytopenias (anaemia, neutropenia, and/or thrombocytopenia), and abnormal cellular maturation. The incidence of this disease group increases with increasing age, and physicians should have knowledge about it. MDS is one of the interesting topics in the field of hematology. This article, which evaluates the publications on this subject in our country and in the world with bibliometric evaluation, aims to give direction to those who work and will work on this subject.
Material and Method: Scopus bibliometric database was scanned. Original research articles, which include the keywords “myelodysplastic syndrome” and “Article” in the title, abstract and keywords, were reached between 1954-2021. Publications were elevuated due to their institution, author, publication year, subject, number of citations and published journal.
Results: It was determined that there were 33,518 publications on MDS and the first publication was published in the year 1954. 22,033 of these publications were original research papers. The United States (USA) (n=6998, 31.8%) was the most scientifically productive country in this regard. The three leading institutions with the most articles on this subject are; University of Texas Dr Anderson Cancer Center (4.7%), Fred Hutchinson Cancer Research Center (2.2%), and Dana-Farber Cancer Institute (2.1%). 1297 of the articles on MDS were cited at least 100 times. The most cited article received 4574 citations. Our country was in 19th place and 328 articles were published. After the year 2000, there was a rapid increase in the number of publications and the highest number of publications (28 articles) was published in 2020. The highest number of articles (17 articles) from our country was published in the Turkish Journal of Hematology.
Conclusion: It is understood that the studies originating from Turkey should be increased numerically and should be placed higher in the ranking.

Anahtar Kelimeler

• Myelodysplastic syndrome
• bibliometry
• SCOPUS

Scopus Veri Tabanına Dayalı Bibliyometrik Değerlendirme: Miyelodisplastik Sendrom Konulu Yayınların Global Analizi ve Türkiye Kaynaklı Yayınların Değerlendirilmesi

Öz

Amaç: Miyelodisplastik sendrom (MDS) hematoloji alanının ilgi çeken konu başlıklarındandır. Bu çalışmada, MDS hakkındaki bilimsel litetarürün gözden geçirilmesini amaçladık.

Yöntem: Scopus bibliyometrik veri tabanında İngilizce dilinde tarama yapıldı. Başlık, özet ve anahtar kelimelerinde "myelodysplastic syndrome" ve "Article" anahtar kelimeleri içeren, 1954-2021 yılları arasında yapılmış orijinal araştırma makalelerine ulaşıldı. Yayınlar; yapıldıkları kurum, yazar, yayın yılı, konu, atıf sayısı ve yayınlandıkları dergi açısından değerlendirildi.

Sonuçlar: Bu konuda; 33.518 yayın olduğu, ilk yayının 1954 yılında yayınlandığı saptandı. Bunların 22.033 tanesi orijinal araştırma makalesi idi. Amerika Birleşik Devletleri (ABD)(n=6998,%31,8) bu konudaki en bilimsel üretken ülke idi. Bu konuda en fazla makalesi bulunan 3 öncü kurum; Texas Üniversitesi Dr Anderson Kanser Merkezi (%4,7), Fred Hutchinson Kanser Araştırma Merkezi (%2,2) ve Dana-Farber Kanser Enstitüsü (%2,1) idi. MDS konulu makalelerin 1297’si en az 100 kez atıf almıştı. En fazla atıfı alan makale 4574 atıf almıştı. Ülkemiz 19. sırada yer almakta olup, 328 makale yayınlanmış idi. 2000 yılından sonra yayın sayısında hızlı bir artış olmuş ve en fazla yayın (28 makale) 2020 yılında yayınlanmıştı. Ülkemizden en fazla sayıda makale (17 makale) Turkish Journal of Hematology’de yayınlanmıştı.

Tartışma: Analiz çalışmamız MDS hakkında yapılan yayınların atıf sayılarının oldukça yüksek olduğu yönünde idi. Bu da araştırmacıları bu konuda yayın yapmaya teşvik edebilir. Ayrıca ülkemizden bu konuda yapılması gereken yayın sayılarının arttırılması gerekmektedir.

Anahtar Kelimeler

• Miyelodisplastik sendrom
• bibliyometri
• SCOPUS

Kaynakça

1. 1. Dotson JL, Lebowicz Y. Myelodysplastic Syndrome. 2020 Aug 11. In: StatPearls Treasure Island (FL): StatPearls Publishing; 2021. [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK534126/
2. 2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-2405.
3. 3. Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010;28(17):2847-2852.
4. 4. Türk Hematoloji Derneği Miyelodisplastik Sendrom Tanı Ve Tedavi Kılavuzu. 2020.[Internet).[ Erişim tarihi: 1 Mayıs 2021]. https://www.thd.org.tr/thdData/userfiles/file/Myelodisplastik%20Sendrom%20Tan%C4%B1%20ve%20Tedavi%20K%C4%B1lavuzu.pdf
5. 5. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
6. 6. Şeref İ, Karagöz B. Scopus veri tabanına dayalı bibliyometrik değerlendirme: Mevlâna Celâleddin Rumî üzerine yapılan araştırmalar. Rumeli DE Dil ve Edebiyat Araştırmaları Dergisi. 2019; (14), 298-313.
7. 7. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682-9. Erratum in: Cancer Res. 1990;50(4):1352.
8. 8. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.

9. 9. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199.
10. 10. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
11. 11. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91(3):756-763.
12. 12. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
13. 13. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
14. 14. Kolb HJ, Schattenberg A, Goldman JM, et al; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995 ;86(5):2041-2050.
15. 15. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
16. 16. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
17. 17. Lonial S, Dimopoulos M, Palumbo A, et al. ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621-631.
18. 18. Rosas SR, Kagan JM, Schouten JT, et al. Evaluating research and impact: a bibliometric analysis of research by the NIH/NIAID HIV/AIDS clinical trials networks. PLoS One. 2011;6(3):e17428.
19. 19. Alkan S, Dindar Demiray EK, Yıldız E, Özlü C. Analysis of Scientific Publications on Acinetobacter bacteremia in Web of Science. Infect Dis Clin Microbiol. 2021; 1: 39-44.
20. 20. Akmal M, Hasnain N, Rehan A, et al. Glioblastome Multiforme: A Bibliometric Analysis. World Neurosurg. 2020;136:270-282.
21. 21. Guo S, Wang L, Xie Y, et al. Bibliometric and Visualized Analysis of Stem Cells Therapy for Spinal Cord Injury Based on Web of Science and CiteSpace in the Last 20 Years. World Neurosurg. 2019;132:e246-e258.
22. 22. Tazegul G, Atas U, Ulas T, et al. Publishing in Hematology Journals: A Scientometric and Economic Evaluation. Cureus. 2020;12(12):e12069.
23. 23. Kawuki J, Yu X, Musa TH. Bibliometric Analysis of Ebola Research Indexed in Web of Science and Scopus (2010-2020). Biomed Res Int. 2020;2020:5476567.
24. 24. Karasözen B, Bayram ÖG, Zan BU. WoS ve Scopus veri tabanlarının karşılaştırması. Türk Kütüphaneciliği. 2011; 25(2), 238-60.